

1 **High-throughput quantification of camelid cytokine mRNA
2 expression in PBMCs by microfluidic qPCR technology**

3 Authors: Jordi Rodon^{1,2}, Nigeer Te^{2, #}, Maria Ballester³, Joaquim Segalés^{1,4}, Júlia
4 Vergara-Alert^{1,2,*}, Albert Bensaid^{1,2}

5

6 Author affiliations: ¹Unitat mixta d'investigació IRTA-UAB en Sanitat Animal, Centre
7 de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de
8 Barcelona (UAB), 08193 Bellaterra, Catalonia, Spain; ²IRTA, Programa de Sanitat
9 Animal, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat
10 Autònoma de Barcelona (UAB), 08193 Bellaterra, Catalonia, Spain; ³Animal Breeding
11 and Genetics Program, Institute for Research and Technology in Food and Agriculture
12 (IRTA), Caldes de Montbui, Spain; ⁴Departament de Sanitat i Anatomia Animals,
13 Facultat de Veterinaria, Universitat Autònoma de Barcelona (UAB), Campus de la
14 UAB, 08193 Bellaterra, Catalonia, Spain.

15

16 Email addresses: J.R. (jordi.rodon@irta.cat); N.T. (tenigeer@hku.hk); M.B.
17 (maria.ballester@irta.cat); J.S. (joaquim.segales@irta.cat); J.V.-A.
18 (julia.vergara@irta.cat) and A.B. (albert.bensaid@irta.cat).

19

20 [#]Current affiliation: School of Public Health, Li Ka Shing Faculty of Medicine, The
21 University of Hong Kong, Hong Kong.

22 *Correspondence should be addressed to J.V.-A. (julia.vergara@irta.cat).

23 **ABSTRACT**

24 Camelids are economically and socially important in several parts of the world and
25 might carry pathogens with epizootic or zoonotic potential. However, biological
26 research in these species is limited due to lack of reagents. Here, we developed RT-
27 qPCR assays to quantify a panel of camelid innate and adaptive immune response
28 genes, which can be monitored in a single run. Validation of the assays was performed
29 with PHA, PMA-ionomycin, and Poly I:C-stimulated PBMCs from alpaca, dromedary
30 camel and llama, including normalization by multiple reference genes. Further,
31 comparative gene expression analyses for the different camelid species were performed
32 by a unique microfluidic qPCR assay. Compared to unstimulated samples, PHA and
33 PMA-ionomycin stimulation elicited robust Th1 and Th2 responses in PBMCs from
34 camelid species. Additional activation of type I and type III IFN signalling pathways
35 was described exclusively in PHA-stimulated dromedary lymphocytes, in contrast to
36 those from alpaca and llama. We also found that PolyI:C stimulation induced robust
37 antiviral response genes in alpaca PBMCs. The proposed methodology should be useful
38 for the measurement of immune responses to infection or vaccination in camelid
39 species.

40

41 **Keywords:** Camelid species, cytokines, immune responses, RT-qPCR, Fluidigm
42 Biomark, PHA, PMA-ionomycin, PolyI:C, dromedary, camel, llama, alpaca

43

44 INTRODUCTION

45 Camelid species are livestock of great economic, sanitary, health and environmental
46 importance in the north of Africa, central Asia, the Middle East, and South America.
47 Number of these animals is expected to grow since the camelid industry is in transition
48 from nomadism to intensive production (FAOSTAT, 2021). In Europe, camelids are
49 used for fine wool production but also kept as pets, guardians of other livestock, or used
50 for recreational or leisure purposes (Halsby et al., 2017). However, these species are
51 susceptible to several viruses, bacteria and protozoan parasites affecting meat and milk
52 production. As an example, Camelpox and Peste des Petits Ruminants viruses are
53 causing recurrent epizootic outbreaks in Africa and Middle East (Khalafalla, 2017).
54 Furthermore, there is limited information available about the role of camelids in the
55 epidemiology of zoonotic diseases. In recent years, the most studied pathogens causing
56 zoonotic diseases included the Middle East respiratory syndrome coronavirus (MERS-
57 CoV), Rift Valley fever virus (RVFV), *Brucella* sp., and *Echinococcus granulosus* (Zhu
58 et al., 2019). Many other less studied viruses known to be carried and transmitted by
59 camelids, such as hepatitis E virus (HEV) or Crimean-Congo haemorrhagic fever virus
60 (CCHFV), are of serious human health concern as well. Camelids are also hosts of
61 many other fastidious bacterial diseases including tuberculosis, gastrointestinal illnesses
62 caused by verotoxin-producing *E. coli*, campylobacteriosis, listeriosis and
63 salmonellosis, among others, as well as protozoan parasites (*Cryptosporidium* spp.,
64 *Sarcoptes*, *Giardia duodenalis*, etc.) of veterinary and human health concern
65 (Khalafalla, 2017).
66 Understanding disease pathogenesis and identifying protective immune responses are
67 prerequisites for the rational development of new anti-microbial drugs and vaccines. In
68 addition, comparison of immune responses between humans and domestic or wildlife

69 species would shed insights to delineate host factors involved in disease outcome. Upon
70 pathogen infection, the host immune system is regulated by complex mechanisms in
71 which cytokines play a pivotal role in determining the intensity and duration of the
72 immune response (Dinarello, 2007; Svanborg et al., 1999). In some domestic species,
73 such as pig, goat, cattle, and sheep, the quantification of cytokines, either at the protein
74 or mRNA level, has become a widely used method to monitor immune responses upon
75 pathogen infection (Smeed et al., 2007; van Reeth & Nauwynck, 2000). However,
76 cytokine detection in camelids has been hampered by the lack of specific reagents.

77 To date, there are few reliable commercial ELISA kits available to study immune
78 responses in camelids at the protein level. Nonetheless, camelid interferon (IFN)- α , and
79 some Th1 and Th2 cytokines, and pro-inflammatory cytokine cDNAs have been cloned
80 and sequenced (Nagarajan et al., 2012; Odbileg et al., 2006; Odbileg, Konnai, et al.,
81 2005; Odbileg, Lee, et al., 2004, 2005; Premraj et al., 2020). Sets of primers have been
82 derived from these sequences (Odbileg, Konnai, et al., 2004) to quantify cytokine
83 mRNAs in peripheral blood mononuclear cells (PBMCs) of *Camelus bactrianus* upon
84 vaccination with *Brucella abortus* strain 19 by reverse transcription quantitative
85 polymerase chain reaction (RT-qPCR) assays (Odbileg et al., 2008). Although these
86 previous works provided tools to quantify a few camelid cytokine mRNAs, primer
87 assays only allow for a cursory study of immune response pathways and were not
88 optimized to function in high-throughput qPCR platforms. We previously took
89 advantage of well-annotated camelid draft genomes (Wu et al., 2014) to design a
90 comprehensive set of primers from genes encompassing several innate immune
91 response pathways (Te et al., 2021, 2022), and demonstrated their usefulness in
92 respiratory tract samples of alpacas. Here, we extended this panel of primers to
93 characterize the expression of innate and adaptive immune response genes in

94 phytohemagglutinin (PHA), phorbol 12-myristate 13-acetate (PMA)-ionomycin and/or
95 PolyI:C-stimulated PBMCs from three different camelid species (dromedaries, llama,
96 and alpacas). We optimized gene expression analyses in the highly sensitive and cost-
97 effective Fluidigm Biomark microfluidic qPCR system. A full validation and
98 standardization of these assays is provided together with an interspecies comparison,
99 characterizing camelid cytokine expression with non-specific PBMC stimuli widely
100 used in immunological research.

101

102 **MATERIALS AND METHODS**

103 The present work was performed using the nomenclature and following the validation
104 protocols proposed by the Minimum Information for publication of quantitative real-
105 time PCR experiments (MIQE) guidelines (Bustin et al., 2009).

106 **Animal welfare, ethics, and experimental design**

107 Experiments with animals were performed at animal facilities of IRTA Alcarràs farm
108 (Lleida, Catalonia, Spain) or at the Biosafety Level-3 (BSL-3) facilities of IRTA-
109 CReSA (Barcelona, Catalonia, Spain), and were approved by the Ethical and Animal
110 Welfare Committee of IRTA (CEEA-IRTA) and by the Ethical Commission of Animal
111 Experimentation of the Autonomous Government of Catalonia (approval No. FUE-
112 2017-00561265 and FUE-2018-00884575).

113 Two llamas (L1, L2) and five alpacas (A1-5) were purchased from Belgium and The
114 Netherlands, respectively, housed at IRTA-CReSA animal facilities and used for
115 routine blood collection. L1 and L2 were used in a previously published study (Rodon
116 et al., 2019), and blood was collected prior experimental infection with MERS-CoV.
117 One healthy dromedary camel (D1) from a private zoo (Alicante, Valencian

118 Community, Spain) was also bled once for routine checking purposes, and extra blood
119 samples were taken to perform this work.

120 **Blood collection**

121 Whole blood samples (40 to 50 mL) from each animal were collected from the jugular
122 vein using EDTA BD Vacutainer® tubes (Beckton Dickinson, New Jersey, USA),
123 following animal welfare protocols.

124 **PBMC isolation**

125 Prior PBMCs isolation, whole blood was diluted 1:1 with phosphate-buffered saline
126 (PBS). PBMCs were harvested from blood by density-gradient centrifugation with
127 Histopaque®-1083 (Sigma-Aldrich, St. Louis, MO, USA), according to the
128 manufacturer's instructions. PBMCs were cultured in RPMI-1640 media supplemented
129 with antibiotics (100 U/mL penicillin, 0.1 mg/mL streptomycin) and glutamine (2
130 mmol/L) purchased from Life Technologies (Waltham, USA), β 2-mercaptoethanol
131 (5×10^{-5} M; Sigma-Aldrich, MO, USA), and 10% heat inactivated foetal calf serum
132 (FCS; EuroClone, Pero, Italy). Cell viability was assessed by the Trypan blue staining
133 exclusion method.

134 **Cell stimulation assays**

135 PBMCs from A1-2, D1, and L1-2 were seeded on 24-well plates at $5 \cdot 10^6$ cells/mL, and
136 cultured in duplicates in medium alone (control condition), or stimulated with 10
137 μ g/mL of PHA (Sigma-Aldrich, St. Louis, MO, USA), or with a combination of 10
138 ng/mL PMA (Sigma-Aldrich, St. Louis, MO, USA) and 1 μ g/mL ionomycin calcium
139 salt (Sigma-Aldrich, St. Louis, MO, USA) for 48 h at 37°C and 5% CO₂. Additionally,
140 PBMCs from A3-5 were cultured with 250 ng/mL Poly(I:C)-LMW/LyoVecTM
141 (PolyI:C; Invivogen, San Diego, USA) for 48 h at 37°C and 5% CO₂. Afterwards,

142 PBMCs were carefully collected by up and down pipetting and transferred to a
143 DNase/RNase-free tube. After centrifugation, supernatants were removed and lysis
144 buffer for RNA extraction was added to the cell pellet. All samples in lysis buffer were
145 stored at -80°C until RNA extraction.

146 **RNA extraction and quantification**

147 Total RNA was extracted from PBMCs using the RNeasy® Mini Kit (Qiagen Ltd.,
148 Crawley, UK), according to the manufacturer's protocol. After RNA elution, an
149 additional DNase I treatment was performed using the Heat&Run gDNA removal kit
150 (ArcticZymes Technologies, Tromsø, Norway), following the manufacturer's protocol.
151 Finally, RNase inhibitors (Invitrogen, Life Technologies, Waltham, USA) were added
152 to the RNA samples in a final concentration of 1 U/µL prior storage at -80°C until
153 reverse transcription (RT) reaction was performed.

154 The purity, quantity and integrity of the extracted RNA were assessed using a BioDrop
155 *µ*LITE Spectrophotometer (BioDrop Ltd, Cambridge, UK) and Lab-Chip analysis
156 (Agilent Technologies, Santa Clara, USA). The A260:A280 ratio ranged from 1.6 to
157 2.1, and RNA Integrity Numbers (RIN) ranged from 7 to 9.6.

158 **cDNA synthesis**

159 Total RNA samples were used to generate cDNA as previously described (Te et al.,
160 2021). Briefly, 110 ng of RNA were retrotranscribed in a final volume of 10 µL using
161 the PrimeScript RT reagent Kit (Takara, Kusatsu, Japan) with a combination of oligo-
162 d(T) and random hexamers, according to the manufacturer's protocol. No-reverse
163 transcription controls (no-RT) with all buffers and reagents supplied by the kits, but
164 omitting the reverse transcriptase, were prepared to assess non-specific amplifications
165 and presence of genomic DNA (gDNA).

166 Additionally, control cDNA samples from stimulated PBMCs were obtained with the
167 aim to generate standard curves and determine primer pair efficiencies. Samples were
168 pooled by species at the same proportion per individual animal, except for the
169 dromedary camel. For each species, pools contained cDNA samples from PMA-
170 ionomycin and PHA-stimulated PBMCs at 1:1 proportion, while alpaca PBMCs
171 stimulated with PolyI:C were pooled independently. Finally, samples were serially
172 diluted by 1:4 steps (1/20, 1/80, 1/320, 1/1280, 1/5120) prior amplification reactions.

173 **Primer design of immune associated and reference genes**

174 Camelid genes and mRNA were found through bibliographic search or with described
175 mRNAs in other species performing BLASTn (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).
176 Primers were designed through comparative genomics of sequences deposited at the
177 National Centre for Biotechnology Information (NCBI) GenBank database of llama
178 (*Lama glama*), alpaca (*Vicugna pacos*), dromedary camel (*Camelus dromedarius*),
179 bactrian camel (*Camelus bactrianus*), and wild bactrian camel (*Camelus ferus*).
180 Comparison of mRNA and genomic sequences of each studied gene were performed
181 with the alignment tool ClustalW to determine exon boundaries. In some instances,
182 exons were already annotated in camelid genomes.

183 Primer pairs were designed with Primer3 (<http://bioinfo.ut.ee/primer3-0.4.0/>), Primer-
184 Blast (<https://www.ncbi.nlm.nih.gov/tools/primer-blast>), or Primer Express 2.0
185 (ThermoFisher Scientific, Life Technologies, Waltham, USA), according to the
186 following desirable criteria: (i) to span two or more exons, and some of them were
187 placed at the exon-exon boundaries, (ii) 17-23 nucleotides in length, close to the mRNA
188 3' end when possible, (iii) GC-content percentage between 45 and 55%, (iv) leading to
189 an approximate 80-200 bp PCR product, (v) melting temperature (Tm) of each primer
190 between 57-63°C with less than 2°C difference within primer pairs, and (vi) avoiding

191 primer hairpin, self-primer dimer or cross-primer dimer formation.

192 The avoidance of primer secondary structure arrangement was assessed through the

193 Beacon DesignerTM program

194 (<http://www.premierbiosoft.com/qOligo/Oligo.jsp?PID=1>), selecting for primers with

195 ΔG greater than -3.5 kcal/mol when possible. Further, primer sequence specificity was

196 assessed using the BLASTn alignment tool against all camelid genome sequences.

197 Potential transcription of predicted pseudogenes was assessed by carrying out promoter

198 region analyses through the VISTA (<http://genome.lbl.gov/vista/customAlignment.shtml>) and the Promoter 2.0 Prediction Server

199 (<http://www.cbs.dtu.dk/services/Promoter>) softwares. Finally, the primer position

200 within exons was checked *in silico* with their respective camelid gene sequences from

201 the NCBI GenBank using the MapViewer tool. All the primers designed in this study

202 are summarized in Table1. Table S1 compiles GenBank accession numbers of camelid

203 genes and mRNA used in this study. Table S2 compiles the principal characteristics of

204 genes and derived primers used in this study. Oligonucleotides used in this study were

205 supplied by Roche Diagnostics (Sant Cugat del Vallès, Barcelona, Spain).

207 **Cytokine quantification by Fluidigm Biomark microfluidic RT-qPCR**

208 cDNA obtained from PBMCs samples were used to validate the whole panel of primers

209 designed for camelid species and to quantify gene expression levels by a microfluidic

210 qPCR technique. Firstly, cDNA samples were pre-amplified using the TaqMan PreAmp

211 Master Mix (Applied Biosystems, Life Technologies, Waltham, USA), following the

212 manufacturer's recommendations, doing an initial activation step of the AmpliTaq Gold

213 DNA Polymerase for 10 min at 95°C, followed by 16 cycles of 15 seconds denaturation

214 at 95°C plus 4 min annealing and extension at 60°C. Pre-amplified products were

215 treated with Exonuclease I (New England Biolabs, Ipswich, USA) for 30 min at 37°C

216 to eliminate the carryover of unincorporated primers. An inactivation step of the
217 enzyme for 15 min at 80°C was included according to the manufacturer's protocol. The
218 96.96 Dynamic Array IFCs, the 96.96 DNA Binding Dye Sample/Loading Kit
219 (Fluidigm Corporation, South San Francisco, USA) was prepared according to the
220 manufacturer's instructions. Pre-amplified samples were diluted 1/20 in 1x TE Buffer,
221 and aliquots of 2.25 µL of each sample and 0.6 µL of primer pairs at 100 µM were
222 loaded in duplicates into their respective array inlets. Quantification of PCR reactions
223 was performed on a Biomark HD system (Fluidigm Corporation, South San Francisco,
224 USA). The PCR consisted in an initial activation step of 1 min at 95°C, followed by 30
225 cycles of 5 seconds at 96°C plus 1 min at 60°C. A dissociation step, increasing 1°C
226 every 3 seconds from 60 to 95°C, was included for all reactions to confirm single
227 specific PCR product amplification and define the Tm of each amplicon. Additionally,
228 stimulated control samples were assayed in triplicates to create relative standard curves
229 and calculate primer amplification efficiencies (see Table S3). No-RT controls and no-
230 RNA template controls (NTC) were included in each assay to check for non-specific
231 amplification or primer-dimer formation.

232 **Relative quantification and data analysis**

233 Expression data was collected with the Fluidigm Real-Time PCR analysis software
234 4.1.3 (Fluidigm Corporation, South San Francisco, USA). Cycle of quantification (Cq)
235 threshold detection value was set at 0.020, quality threshold cut-off value was
236 established at 0.65 and amplification specificity was assessed by Tm analyses for each
237 reaction. Amplifications fulfilling the above criteria were analysed using the DAG
238 expression software 1.0.5.6 (Ballester et al., 2013) to apply the relative standard curve
239 method (Livak, 1997). Cq values obtained from pooled cDNA controls were used to
240 create standard curves for each gene, species and PBMC stimulation condition, and to

241 extrapolate the relative quantity values. R-squared values were determined for each
242 standard curve and the specific PCR efficiencies were calculated by applying the
243 formula $(10^{(-1/\text{slope value})-1}) * 100$ (see Table S3). Multiple reference gene
244 normalization was performed by using glyceraldehyde-3-phosphate dehydrogenase
245 (*GAPDH*), hypoxanthine phosphoribosyltransferase (*HPRT1*) and ubiquitin C (*UBC*) as
246 endogenous controls. Their suitability for normalization procedures was assessed by
247 control-gene stability analyses with the DAG expression software 1.0.5.6 (Ballester et
248 al., 2013). The normalized quantity values of each sample and assay were used for
249 direct comparison in relation to non-stimulated PBMCs samples cultured during 48 h.
250 Therefore, the up- or down-regulated expression of each gene was expressed in fold
251 changes (Fc).

252 Statistical analyses could only be applied in results from alpaca PBMCs cultured with
253 PolyI:C stimulus, due to the sample size. Fc values were logarithmically transformed to
254 achieve normal distributions. Means of the transformed fold changes obtained for
255 stimulated and unstimulated conditions were compared using unpaired t-test analyses in
256 R and GraphPad Prism softwares. Differences were considered significant at p -values <
257 0.05.

258

259 **RESULTS**

260 **Selection of immune-related genes and primer design**

261 The selected genes encompassed several functional categories representative of
262 pathogen innate and adaptive immune responses, and comprised type I, II and III IFNs,
263 pattern recognition receptors (PRRs), transcription factors (TFs), IFN-stimulated genes
264 (ISGs), pro- and anti-inflammatory cytokines, enzymes, adaptors, cellular receptors,
265 and other genes involved in Th1 and Th2 responses. In addition, three reference genes,

266 *GAPDH*, *HPRT1* and *UBC*, were selected to normalize gene expression. Table 1

267 summarizes genes and primers designed for subsequent expression analyses.

268 Primer sets were designed to anneal in conserved transcribed regions of genes from five
269 camelid species (alpaca, Bactrian camel, dromedary camel, llama, and wild Bactrian
270 camel). Some of the genes were not annotated in the genome of llama (see Table S1)
271 but exon/intron boundaries could be found by performing a BLASTn with the mRNA
272 of other camelid species. The main features of the designed primer pairs are listed in
273 Table S2.

274 **Primer amplification efficacy and specificity**

275 Pools of cDNAs prepared from stimulated PBMCs were used to evaluate the whole
276 panel of primers in samples from alpaca, dromedary, and llama. Number of dilutions
277 used for the generation of each standard curve, slopes, coefficients of determination and
278 amplification efficiencies are listed in Table S3. After 48 h of PBMC stimulation, all
279 gene transcripts were sufficiently expressed to generate standard curves using 3 to 5
280 serial dilutions, except for *IFNAR1* in samples from dromedary and *IFN-λ1* in those
281 from dromedary camel and llama (Table S3). *IFN-λ3* was not expressed in PBMCs
282 from any species, regardless of the stimuli type (Table S3). All calibration curves
283 produced linear standard curves, as evidenced by high coefficients of determination
284 (>0.95, except for 1 sample that was 0.886). Primer pairs resulted in optimal
285 amplification efficiencies in the different camelid species, ranging from 69 to 100%.
286 Tm analyses confirmed a single specific amplicon for all amplified gene transcripts in
287 all three camelid species. No amplifications occurred in no-RT and NTC samples
288 included in the microfluidic RT-qPCR assays. Thus, most of the designed primer pairs
289 targeting camelid cytokines and immune-related genes, as well as endogenous genes,
290 displayed optimal specificity and efficacy suitable for immune response studies in

291 camelid PBMCs.

292 **Gene expression analyses of llama PBMCs by microfluidic RT-qPCR**

293 Transcriptomic gene expression profile of llama PBMCs stimulated for 48 h with PHA
294 and PMA-/ionomycin were compared to those of unstimulated cells. Relative expression
295 of the different genes grouped by functional categories is shown in Figure 1a-j. PHA
296 and PMA-/ionomycin stimulation provoked similar gene expression profiles in llama
297 PBMCs. Both stimuli induced expression of *IFN- γ* at high levels (114 and 123 Fc,
298 respectively), but none of the other type I or III IFNs were upregulated (Figure 1a).
299 Within the category of ISGs, *CXCL10* expression was induced by PHA and PMA-
300 ionomycin and *MX1* only by PHA stimulated samples (Figure 1c). PHA and PMA-
301 ionomycin also provoked the upregulation of *CCL3*, *TNF- α* , *IRF7* and *NFKB1* (Figure
302 1d, e and f). High levels of *IL-6* (Fc of 79.82 and 62.47), *IL-2* (Fc of 71.32 and 80.30)
303 and *IL-4* (Fc of 195.78 and 145.58) expression were found of PHA and PMA-
304 ionomycin stimulation, respectively (Figure 1e and j). Transcription of other pro- or
305 anti-inflammatory cytokines, PRRs, adaptors, enzymes and IFN receptors were not
306 induced in llama stimulated PBMCs (Figure 1b, e, g, h and i). Globally, the results
307 obtained in llama cells were according to the expectancy that PHA and PMA-
308 ionomycin provoke a marked polyclonal stimulation of PBMCs.

309 **Gene expression analyses of alpaca PBMCs by microfluidic RT-qPCR**

310 We utilized the same methodology to study immune gene expression in alpaca. Gene
311 expression profile of stimulated PBMCs (PHA, PMA-ionomycin and PolyI:C) were
312 compared to that of unstimulated cells (Figure 2a-j). PHA and PMA-ionomycin
313 stimulation triggered an upregulation of *RIG-1*, *MDA5*, *MX1*, *ISG15*, *CXCL1*, and *IL-8*
314 compared to non-stimulated samples cultured for 48 h (Figure 2b, c, d, e). Moreover,

315 expression of *IFN-β*, *IFN-γ*, *IL-10*, *IL-6*, *STAT-1*, *IRF7*, *NFKB1*, *CASPI*, *IL-2* and *IL-4*
316 was more markedly upregulated in PHA-stimulated PBMCs (Figure 2a, e, f, h and j).

317 On the other hand, PMBCs from three additional alpacas were cultured with PolyI:C to
318 ensure functionality of primers targeting mRNA of impasse genes to PHA or PMA-
319 ionomycin stimulation. PolyI:C exposure for 48 h resulted in the upregulation of
320 different immune genes when compared with the previous polyclonal stimulations
321 (*IFN-α*, *IFN-β*, *RIG-1*, *MDA5*, *TLR3*, *TLR7*, *CXCL10*, *MX1*, *OAS1*, *ISG15*, *IL-10*, *IL-6*,
322 *STAT1* and *IRF7*), some of them being expressed at high levels such as *IFN-β* (83.72
323 Fc), *MX1* (30.68 Fc) and *ISG15* (62.34 Fc) (Figure 2a-f). Moreover, statistical analyses
324 determined a significant increase in *IFN-β*, *RIG-1*, *MDA5*, *TLR7*, *NLRP3*, all ISGs,
325 *STAT1* and *IRF7* expression levels compared to non-stimulated alpaca PBMCs.
326 Therefore, these results confirmed Poly I:C as a good *in vitro* immunostimulant of
327 antiviral responses in alpaca PBMCs.

328 **Gene expression analyses of dromedary PBMCs by microfluidic RT-qPCR**

329 Expression of dromedary immune genes in stimulated PBMCs were compared to that of
330 unstimulated cells (Figure 3a-j). Dromedary cells stimulated with PHA and PMA-
331 ionomycin displayed similar transcriptomic profiles with characteristics of classical
332 polyclonal stimulations. Relative to non-stimulated control samples, both PHA and
333 PMA-ionomycin stimuli provoked the induction of *IFN-β*, *IFN-γ*, *CCL3*, *CXCL1*, *IL-6*,
334 *IL-8*, *TNF-α*, *MIF*, *NFKB1*, *NFKB1A* and *IL-4* in higher relative expression levels than
335 unstimulated PBMCs (Figure 3a, d, e, f, g and j). In addition, specific PHA stimulation
336 led to increased mRNA levels of *IFN-α*, *IFN-λ1*, *RIG-1*, *MDA5*, *CXCL10*, *MX1*, *OAS1*,
337 *ISG15*, *IL-10*, *IL-1β*, *IRF7* and *TRIM25*, while transcription of *IL-2* was markedly
338 induced in PMA-ionomycin stimulated PBMCs of dromedary camels (Figure 3a, b, c, e,
339 f, h and j). Overall, dromedary PBMCs were properly stimulated by PHA and PMA-

340 ionomycin, enhancing immune-related gene expression in accordance with regular
341 polyclonal stimulations.

342

343 **DISCUSSION**

344 Due to the lack of reagent availability (i.e., antibodies) in several animal species,
345 analysis of gene expression has become a common method to determine the immune
346 transcriptomic profile after infection and/or vaccination. In this work, we implemented
347 an RT-qPCR method to monitor camelid innate and adaptive immune responses, which
348 allow the quantification of forty-seven cytokines and immune-related genes in a single
349 run. Importantly, the designed primer sets can be used for all camelid species using the
350 same conditions (primer hybridization temperature) and methodology.

351 Several infectious diseases affect camelid species and threaten livestock productivity
352 (Camel pox virus, trypanosomiasis, and gastro-intestinal helminthiases, among others).

353 Also, camelids are a source for several zoonotic viral and bacterial pathogens (MERS-
354 CoV, Crimean-Congo haemorrhagic fever virus, *Rickettsia* spp, and others) which
355 threaten public health (Khalafalla, 2017; Wernery et al., 2014). However, immune
356 responses elicited upon infections of camelids remain largely unknown. Although a
357 previous work provided tools to quantify inflammatory cytokines mRNA from llama
358 (Odbileg, Konnai, et al., 2004), the primers were designed before available annotation
359 of camelid genomes (Wu et al., 2014). Therefore, we designed new primers sets to
360 perform more accurate assays.

361 First, we focused on the requirements to ensure a specific amplification of the products
362 (Taylor et al., 2010) and established criteria for the subsequent design of primers.

363 Although not all primer designs fulfilled all parameters of the criteria (i.e., genes with a

364 single exon as IFNs α , β , and $\lambda 1$), specific amplification was determined together with
365 the absence of amplification in no-RT and NTC controls, which ensured that gDNA
366 amplification did not occur. In addition, three reference genes, (*GAPDH*, *HPRT1* and
367 *UBC*) were selected to normalize gene expression (Cincinnati et al., 2008; Mehta et al.,
368 2010; Souza et al., 2013). These genes have been reported to be stable for data
369 normalization in T lymphocytes (Albershardt et al., 2012; Bas et al., 2004; Dheda et al.,
370 2004) and respiratory samples (Resa et al., 2014; Te et al., 2021). Choosing appropriate
371 reference genes is crucial to achieve optimal data normalization, which is mandatory to
372 discard sample-to-sample variations. Here, the selected normalizer genes were stable in
373 PBMC samples from all the studied species, regardless the type of stimulation.

374 The designed primers would allow studying camelid immune responses in most
375 laboratories worldwide, including those in developing countries, which have been
376 infrastructurally and technically upgraded to perform PCR-based assays since the
377 recent influenza virus outbreaks and the COVID-19 pandemics (Breiman et al., 2007).
378 Nonetheless, to study expression analyses of a broad panel of genes in multiple samples
379 by the gold standard RT-qPCR can result tedious and relatively expensive. Thus, we
380 integrated the whole set of designed primers in a unique Fluidigm Biomark
381 microfluidic qPCR assay. Gene expression analyses showed that PHA and PMA-
382 ionomycin stimulation produced strong induction of some cytokines and immune gene
383 transcripts in camelid PBMCs, which displayed profiles commonly found in
384 polyclonally activated lymphocytes of bovine (Norian et al., 2015) and human
385 (Rostaing et al., 1999). PBMCs from dromedary camel and llama underwent a robust
386 increase in *IFN- γ* , *IL-4* and *IL-6* expression after PHA and PMA-ionomycin exposure,
387 and the same phenomenon occurred in alpaca PBMCs stimulated with PHA but not
388 with PMA-ionomycin. Transcription of the pro-inflammatory *IL-8* and the anti-

389 inflammatory *IL-10* was also upregulated in polyclonally-stimulated alpaca and
390 dromedary cells, but not in those from llama. Upregulation of *IL-8* in camelid cells was
391 expected since it is tightly regulated upon activation of the transcription factor NF-κB
392 (Liu et al., 2017). Similar to previous results in humans (Baran et al., 2001), *IL-10*
393 expression was only upregulated by PHA stimulation but PMA-/ionomycin was
394 ineffective. Furthermore, it is known that type I and III IFNs activate a different
395 signalling pathway than *IFN-γ* does, which can lead to the expression of distinct ISGs
396 (Sen et al., 2018; W. Wang et al., 2017). *CXCL10* and *CCL3* are typically classified as
397 ISGs induced by *IFN-γ* (Rabin, 2003; Sen et al., 2018). Upregulation of these
398 chemokines was observed in all dromedary and llama samples expressing high levels of
399 *IFN-γ*, apart from *CXCL10* in dromedary cells stimulated with PMA-/ionomycin. As
400 reported here, the stimulation of camelid cells using PHA and PMA-/ionomycin did not
401 activate the transcription of PRRs, adaptors, enzymes and IFN receptors compared to
402 unstimulated controls. As observed in other mammalian species (Ciliberti et al., 2017;
403 Gao et al., 2010; Lin et al., 2021; Norian et al., 2015; Wagner & Freer, 2009), PHA and
404 PMA-/ionomycin are also potent antigen surrogate activators of Th1 and Th2 cytokine
405 expression in alpaca, dromedary, and llama PBMCs. Our results support that PHA and
406 PMA-/ionomycin can be used to monitor camelid T-cell activation, proliferation, and
407 effective cytokine production.

408 Curiously, a broader gene expression profile was observed in dromedary PBMCs 48 h
409 after PHA stimulation. Besides the activation of type II IFN signalling pathway, PHA
410 also upregulated the expression of type I and III IFNs, as well as downstream genes
411 regulated upon the IFN signalling cascade activation. Consequently, strong induction of
412 PRRs and ISGs occurred in dromedary samples but not in those from alpaca or llama.
413 Expression of *IRF7* and *IL-10* were also exclusively upregulated in PHA-stimulated

414 dromedary PBMCs, in agreement with previous reports showing that both type I and III
415 IFNs increase the transcription of *IRF7* factor *in vitro* (Zhou et al., 2007), and that IL-
416 10 production is enhanced as a type III IFN-stimulated gene (Stanifer et al., 2019).
417 Further analyses involving samples from more animals would help to rule out
418 individual animal variations to confirm whether dromedary camels have a broader
419 immune response after PHA stimulation than other camelid species.

420 *In vitro* stimulation of PBMCs with PolyI:C is known to elicit the expression of
421 cytokines, mimicking certain aspects of viral infection (Huang et al., 2006). After 48 h
422 stimulation, alpaca PBMCs sensed PolyI:C and increased the expression of type I IFNs,
423 all studied PRRs and ISGs, along with the transcription factors *STAT1* and *IRF7*.
424 Contrary to human PBMCs (Murata et al., 2014), alpaca lymphocytes exposed to
425 PolyI:C induced type I but not type III IFNs. Previous investigations indicated that
426 *IFN- α* was not produced by ovine and bovine PBMCs treated with PolyI:C (Booth et
427 al., 2010), hence future studies could shed light on differential antiviral immune
428 responses among livestock species. Globally, PolyI:C stimulation of alpaca PBMCs
429 yielded similar results than porcine and human PBMCs did (Docampo et al., 2017;
430 Huang et al., 2006; J. Wang et al., 2016). Thus, Poly I:C is a good immunostimulant of
431 antiviral responses in alpaca PBMCs. Further research is needed to determine if other
432 camelid species are equally responsive to Poly I:C.

433 In the current work, regardless of the stimuli used to boost cytokine expression, none of
434 the PBMC stimulation assays in any camelid species showed detectable levels of *IFN-*
435 $\lambda 3$ expression. However, we previously demonstrated an optimal amplification of *IFN-*
436 $\lambda 3$ mRNA in the nasal epithelium of MERS-CoV infected alpacas (Te et al., 2021,
437 2022) using the pair of primers reported here. Primers targeting *IFN- $\lambda 3$* were also
438 designed to anneal mRNA of all camelid species, therefore, a correct amplification is

439 also expected in samples from other camelids, although further studies are needed to
440 confirm this hypothesis.

441 In summary, we implemented a RT-qPCR method for the simultaneous quantification
442 of cytokines and immune-related genes involved in major immune response signalling
443 pathways of different camelid species. The novel assay was set up after the design of
444 primers targeting immune genes and performing data normalization with three
445 reference genes. The assays were validated using PBMCs from alpaca, dromedary
446 camel and llama PBMCs after stimulation with PHA, PMA-/ionomycin or PolyI:C.
447 Microfluidic RT-qPCR results indicated that PBMCs from all camelid species
448 stimulated with PHA and PMA-/ionomycin induce genes characteristic of Th1 and Th2
449 responses, besides PHA activation of type I and III IFN signalling pathways in
450 dromedary lymphocytes. PolyI:C stimulation produced a marked antiviral response in
451 alpaca PBMCs.

452

453 **ACKNOWLEDGEMENTS**

454 The authors thank Joana Ribes from the Centre for Research in Agricultural Genomics
455 (CRAG, Cerdanyola del Vallès, Barcelona) for her technical guidance in the use of
456 Fluidigm BioMark technology. This study was performed as part of the Zoonotic
457 Anticipation and Preparedness Initiative (ZAPI project) [Innovative Medicines initiative
458 (IMI) grant 115760] and the Veterinary Biocontained research facility Network
459 (VetBioNet) project (EU Grant Agreement INFRA-2016-1 N°731014), with assistance
460 and financial support from IMI and the European Commission and contributions from
461 EFPIA partners. J.R. was partially supported by the VetBioNet project. IRTA is
462 supported by CERCA Programme / Generalitat de Catalunya.

463

464 **AUTHOR CONTRIBUTIONS**

465 J.R., J.S., J.V.-A. and A.B. conceived and designed the study. J.R., N.T., M.B., A.B.,
466 J.S., J.V.-A and A.B. performed the experiments and analyzed the data. All the authors
467 discussed the results. The manuscript was written by J.R. and all the authors revised the
468 manuscript.

469

470 **REFERENCES**

471 Albershardt, T. C., Iritani, B. M., & Ruddell, A. (2012). Evaluation of reference genes
472 for quantitative PCR analysis of mouse lymphocytes. *Journal of Immunological
Methods*, 384(1–2), 196–199. <https://doi.org/10.1016/j.jim.2012.07.020>

473

474 Ballester, M., Cordón, R., & Folch, J. M. (2013). DAG expression: High-throughput
475 gene expression analysis of real-time PCR data using standard curves for relative
476 quantification. *PLoS ONE*, 8(11), 8–12.
477 <https://doi.org/10.1371/journal.pone.0080385>

478 Baran, J., Kowalczyk, D., Ozog, M., & Zembala, M. (2001). Three-color flow
479 cytometry detection of intracellular cytokines in peripheral blood mononuclear
480 cells: Comparative analysis of phorbol myristate acetate-ionsomycin and
481 phytohemagglutinin stimulation. *Clinical and Diagnostic Laboratory Immunology*,
482 8(2), 303–313. <https://doi.org/10.1128/CDLI.8.2.303-313.2001>

483 Bas, A., Forsberg, G., Hammarström, S., & Hammarström, M.-L. (2004). Utility of the
484 housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-
485 dehydrogenase for normalization in real-time quantitative reverse transcriptase-
486 polymerase chain reaction analysis of gene expression in human T lymphocytes.
487 *Scandinavian Journal of Immunology*, 59(6), 566–573.

488 <https://doi.org/10.1111/j.0300-9475.2004.01440.x>

489 Booth, J. S., Buza, J. J., Potter, A., Babiuk, L. A., & Mutwiri, G. K. (2010). Co-

490 stimulation with TLR7/8 and TLR9 agonists induce down-regulation of innate

491 immune responses in sheep blood mononuclear and B cells. *Developmental and*

492 *Comparative Immunology*, 34(5), 572–578.

493 <https://doi.org/10.1016/j.dci.2009.12.018>

494 Breiman, R. F., Nasidi, A., Katz, M. A., Njenga, M. K., & Vertefeuille, J. (2007).

495 Preparedness for Highly Pathogenic Avian Influenza Pandemic in Africa.

496 *Emerging Infectious Disease Journal*, 13(10), 1453.

497 <https://doi.org/10.3201/eid1310.070400>

498 Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller,

499 R., Nolan, T., Pfaffl, M. W., Shipley, G. L., Vandesompele, J., & Wittwer, C. T.

500 (2009). The MIQE guidelines: Minimum information for publication of

501 quantitative real-time PCR experiments. *Clinical Chemistry*, 55(4), 611–622.

502 <https://doi.org/10.1373/clinchem.2008.112797>

503 Cincinnati, V. R., Shen, Q., Sotiropoulos, G. C., Radtke, A., Gerken, G., & Beckebaum,

504 S. (2008). Validation of putative reference genes for gene expression studies in

505 human hepatocellular carcinoma using real-time quantitative RT-PCR. *BMC*

506 *Cancer*, 8, 350. <https://doi.org/10.1186/1471-2407-8-350>

507 Ciliberti, M. G., Albenzio, M., Inghese, C., Santillo, A., Marino, R., Sevi, A., &

508 Caroprese, M. (2017). Peripheral blood mononuclear cell proliferation and

509 cytokine production in sheep as affected by cortisol level and duration of stress.

510 *Journal of Dairy Science*, 100(1), 750–756. <https://doi.org/10.3168/jds.2016-11688>

511 Dheda, K., Huggett, J. F., Bustin, S. A., Johnson, M. A., Rook, G., & Zumla, A. (2004).

512 Validation of housekeeping genes for normalizing RNA expression in real-time

513 PCR. *BioTechniques*, 37(1), 112–119.

514 <https://doi.org/http://dx.doi.org/10.1016/j.ymeth.2010.01.003>

515 516 Dinarello, C. A. (2007). Historical insights into cytokines. *European Journal of Immunology*, 37(S1), S34–S45.

517 <https://doi.org/https://doi.org/10.1002/eji.200737772>

518 519 520 Docampo, M. J., Cabrera, J., & Bassols, A. (2017). Hyaluronan mediates the adhesion of porcine peripheral blood mononuclear cells to poly (I:C)-treated intestinal cells and modulates their cytokine production. *Veterinary Immunology and Immunopathology*, 184, 8–17. <https://doi.org/10.1016/j.vetimm.2016.12.008>

521 522 Food and Agriculture Organization of the United Nations Statistics Division. (2021). *FAOSTAT Statistical Database*. www.fao.org/faostat

523 524 525 526 527 Gao, Y., Flori, L., Lecandonnel, J., Esquerre, D., Hu, Z. L., Teillaud, A., Lemonnier, G., Lefèvre, F., Oswald, I. P., & Rogel-Gaillard, C. (2010). Transcriptome analysis of porcine PBMCs after in vitro stimulation by LPS or PMA/ionomycin using an expression array targeting the pig immune response. *BMC Genomics*, 11(1), 1–25. <https://doi.org/10.1186/1471-2164-11-292>

528 529 530 531 532 Halsby, K., Twomey, D. F., Featherstone, C., Foster, A., Walsh, A., Hewitt, K., & Morgan, D. (2017). Zoonotic diseases in South American camelids in England and Wales. *Epidemiology and Infection*, 145(5), 1037–1043. <https://doi.org/10.1017/S0950268816003101>

533 534 535 536 Huang, C. C., Duffy, K. E., San Mateo, L. R., Amegadzie, B. Y., Sarisky, R. T., & Mbow, M. L. (2006). A pathway analysis of poly(I:C)-induced global gene expression change in human peripheral blood mononuclear cells. *Physiological Genomics*, 26(2), 125–133. <https://doi.org/10.1152/physiolgenomics.00002.2006>

537 Khalafalla, A. I. (2017). *Emerging Infectious Diseases in Camelids BT - Emerging and*

538 *Re-emerging Infectious Diseases of Livestock* (J. Bayry (ed.); pp. 425–441).

539 Springer International Publishing. https://doi.org/10.1007/978-3-319-47426-7_20

540 Lin, Z., Huang, Y., Jiang, H., Zhang, D., Yang, Y., Geng, X., & Li, B. (2021).

541 Functional differences and similarities in activated peripheral blood mononuclear

542 cells by lipopolysaccharide or phytohemagglutinin stimulation between human and

543 cynomolgus monkeys. *Annals of Translational Medicine*, 9(3), 257–257.

544 <https://doi.org/10.21037/atm-20-4548>

545 Liu, T., Zhang, L., Joo, D., & Sun, S. C. (2017). NF-κB signaling in inflammation.

546 *Signal Transduction and Targeted Therapy*, 2(March).

547 <https://doi.org/10.1038/sigtrans.2017.23>

548 Livak, K. (1997). ABI Prism 7700 Sequence Detection System. *User Bulletin No. 2, PE*

549 *Applied Biosystems*, 4303859B(bulletin reference 1997), 777802–778002.

550 Mehta, R., Birerdinc, A., Hossain, N., Afendy, A., Chandhoke, V., Younossi, Z., &

551 Baranova, A. (2010). Validation of endogenous reference genes for qRT-PCR

552 analysis of human visceral adipose samples. *BMC Molecular Biology*, 11, 39.

553 <https://doi.org/10.1186/1471-2199-11-39>

554 Murata, K., Sugiyama, M., Kimura, T., Yoshio, S., Kanto, T., Kirikae, I., Saito, H.,

555 Aoki, Y., Hiramine, S., Matsui, T., Ito, K., Korenaga, M., Imamura, M., Masaki,

556 N., & Mizokami, M. (2014). Ex vivo induction of IFN-λ3 by a TLR7 agonist

557 determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients.

558 *Journal of Gastroenterology*, 49(1), 126–137. <https://doi.org/10.1007/s00535-013-0814-1>

559 0814-1

560 Nagarajan, G., Swami, S. K., Ghorui, S. K., Pathak, K. M. L., Singh, R. K., & Patil, N.

561 V. (2012). Cloning and sequence analysis of IL-2, IL-4 and IFN-γ from Indian

562 Dromedary camels (*Camelus dromedarius*). *Research in Veterinary Science*, 92(3),

563 420–426. <https://doi.org/10.1016/j.rvsc.2011.03.028>

564 Norian, R., Delirezh, N., & Azadmehr, A. (2015). Evaluation of proliferation and

565 cytokines production by mitogen-stimulated bovine peripheral blood mononuclear

566 cells. *Veterinary Research Forum*, 6(4), 265–271.

567 Odbileg, R., Konnai, S., Ohashi, K., & Onuma, M. (2005). Molecular cloning and

568 phylogenetic analysis of inflammatory cytokines of Camelidae (llama and camel).

569 *The Journal of Veterinary Medical Science / the Japanese Society of Veterinary*

570 *Science*, 67(9), 921–925. <https://doi.org/JST.JSTAGE/jvms/67.921> [pii]

571 Odbileg, R., Konnai, S., Usui, T., Ohashi, K., & Onuma, M. (2004). Quantification of

572 llama inflammatory cytokine mRNAs by real-time RT-PCR. *The Journal of*

573 *Veterinary Medical Science / the Japanese Society of Veterinary Science*, 67(2),

574 195–198. <https://doi.org/JST.JSTAGE/jvms/67.195> [pii]

575 Odbileg, R., Lee, S. Il, Ohashi, K., & Onuma, M. (2005). Cloning and sequence

576 analysis of llama (lama glama): Th2 (IL-4, IL-10 and IL-13) cytokines. *Veterinary*

577 *Immunology and Immunopathology*, 104(3–4), 145–153.

578 <https://doi.org/10.1016/j.vetimm.2004.11.002>

579 Odbileg, R., Lee, S.-I., Yoshida, R., Chang, K.-S., Ohashi, K., Sugimoto, C., & Onuma,

580 M. (2004). Cloning and sequence analysis of llama cytokines related to cell-

581 mediated immunity. *Veterinary Immunology and Immunopathology*, 102(1–2), 93–

582 102. <https://doi.org/10.1016/j.vetimm.2004.06.001>

583 Odbileg, R., Purevtseren, B., Batsukh, Z., Konnai, S., Ohashi, K., & Onuma, M. (2006).

584 Complete cDNA sequences and phylogenetic analyses of the Th1 and Th2

585 cytokines of the bactrian camel (*Camelus bactrianus*). *Journal of Veterinary*

586 *Medical Science*, 68(9), 941–946. <https://doi.org/10.1292/jvms.68.941>

587 Odbileg, R., Purevtseren, B., Gantsetseg, D., Boldbaatar, B., Buyannemekh, T.,

588 Galmandakh, Z., Erdenebaatar, J., Konnai, S., Onuma, M., & Ohashi, K. (2008).

589 Cytokine responses in camels (*Camelus bactrianus*) vaccinated with *Brucella*

590 *abortus* strain 19 vaccine. *The Journal of Veterinary Medical Science / the*

591 *Japanese Society of Veterinary Science*, 70(2), 197–201.

592 <https://doi.org/10.1292/jvms.70.197>

593 Premraj, A., Aleyas, A. G., Nautiyal, B., & Rasool, T. J. (2020). Camelid type I

594 interferons: Identification and functional characterization of interferon alpha from

595 the dromedary camel (*Camelus dromedarius*). *Molecular Immunology*,

596 119(January), 132–143. <https://doi.org/10.1016/j.molimm.2020.01.020>

597 Rabin, R. L. (2003). CC, C, and CX3C Chemokines. In H. L. Henry & A. W. B. T.-E.

598 of H. Norman (Eds.), *Encyclopedia of Hormones* (pp. 255–263). Academic Press.

599 <https://doi.org/https://doi.org/10.1016/B0-12-341103-3/00044-9>

600 Resa, C., Magro, S., Marechal, P., Barranger, Cô., Joannes, M., Miszczak, F., & Vabret,

601 A. (2014). Development of an efficient qRT-PCR assay for quality control and

602 cellular quantification of respiratory samples. *Journal of Clinical Virology*, 60(3),

603 270–275. <https://doi.org/10.1016/j.jcv.2014.03.019>

604 Rodon, J., Okba, N. M. A. A., Te, N., van Dieren, B., Bosch, B.-J. J., Bensaid, A.,

605 Segalés, J., Haagmans, B. L., & Vergara-Alert, J. (2019). Blocking transmission of

606 Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by

607 vaccination with a recombinant spike protein. *Emerging Microbes and Infections*,

608 8(1), 1593–1603. <https://doi.org/10.1080/22221751.2019.1685912>

609 Rostaing, L., Tkaczuk, J., Durand, M., Peres, C., Durand, D., De Préval, C., Ohayon, E.,

610 & Abbal, M. (1999). Kinetics of intracytoplasmic Th1 and Th2 cytokine

611 production assessed by flow cytometry following in vitro activation of peripheral

612 blood mononuclear cells. *Cytometry*, 35(4), 318–328.

613 [https://doi.org/10.1002/\(SICI\)1097-0320\(19990401\)35:4<318::AID-CYTO4>3.0.CO;2-4](https://doi.org/10.1002/(SICI)1097-0320(19990401)35:4<318::AID-CYTO4>3.0.CO;2-4)

614 Sen, N., Sung, P., Panda, A., & Arvin, A. M. (2018). Distinctive Roles for Type I and

615 Type II Interferons and Interferon Regulatory Factors in the Host Cell Defense

616 against Varicella-Zoster Virus. *Journal of Virology*, 92(21).

617 <https://doi.org/10.1128/jvi.01151-18>

618 Smeed, J. A., Watkins, C. A., Rhind, S. M., & Hopkins, J. (2007). Differential cytokine

619 gene expression profiles in the three pathological forms of sheep paratuberculosis.

620 *BMC Veterinary Research*, 3(1), 18. <https://doi.org/10.1186/1746-6148-3-18>

621 Souza, A. F. D., Brum, I. S., Neto, B. S., Berger, M., & Branchini, G. (2013). Reference

622 gene for primary culture of prostate cancer cells. *Molecular Biology Reports*,

623 40(4), 2955–2962. <https://doi.org/10.1007/s11033-012-2366-5>

624 Stanifer, M. L., Pervolaraki, K., & Boulant, S. (2019). Differential regulation of type I

625 and type III interferon signaling. *International Journal of Molecular Sciences*,

626 20(6), 1–22. <https://doi.org/10.3390/ijms20061445>

627 Svanborg, C., Godaly, G., & Hedlund, M. (1999). Cytokine responses during mucosal

628 infections: role in disease pathogenesis and host defence. *Current Opinion in*

629 *Microbiology*, 2(1), 99–103. [https://doi.org/https://doi.org/10.1016/S1369-5274\(99\)80017-4](https://doi.org/https://doi.org/10.1016/S1369-5274(99)80017-4)

630 Taylor, S., Wakem, M., Dijkman, G., Alsarraj, M., & Nguyen, M. (2010). A practical

631 approach to RT-qPCR-Publishing data that conform to the MIQE guidelines.

632 *Methods*, 50(4), S1. <https://doi.org/10.1016/j.ymeth.2010.01.005>

633 Te, N., Rodon, J., Ballester, M., Pérez, M., Pailler-García, L., Segalés, J., Vergara-Alert,

634 J., & Bensaid, A. (2021). Type I and III IFNs produced by the nasal epithelia and

635 dimmed inflammation are features of alpacas resolving MERS-CoV infection.

638 *PLoS Pathogens*, 17(5), 1–28. <https://doi.org/10.1371/journal.ppat.1009229>

639 Te, N., Rodon, J., Pérez, M., Segalés, J., Vergara-Alert, J., & Bensaid, A. (2022).

640 Enhanced replication fitness of MERS-CoV clade B over clade A strains in

641 camelids explains the dominance of clade B strains in the Arabian Peninsula.

642 *Emerging Microbes and Infections*, 11(1), 260–274.

643 <https://doi.org/10.1080/22221751.2021.2019559>

644 van Reeth, K., & Nauwynck, H. (2000). Proinflammatory cytokines and viral

645 respiratory disease in pigs. *Veterinary Research*, 31(2), 187–213.

646 <https://doi.org/10.1051/vetres:2000113>

647 Wagner, B., & Freer, H. (2009). Development of a bead-based multiplex assay for

648 simultaneous quantification of cytokines in horses. *Veterinary Immunology and*

649 *Immunopathology*, 127(3–4), 242–248.

650 <https://doi.org/10.1016/j.vetimm.2008.10.313>

651 Wang, J., Wang, Y., Wang, H., Wang, H., Liu, J. F., Wu, Y., & Guo, J. (2016).

652 Transcriptomic analysis identifies candidate genes and gene sets controlling the

653 response of porcine peripheral blood mononuclear cells to poly I:C stimulation.

654 *G3: Genes, Genomes, Genetics*, 6(5), 1267–1275.

655 <https://doi.org/10.1534/g3.116.028290>

656 Wang, W., Xu, L., Su, J., Peppelenbosch, M. P., & Pan, Q. (2017). Transcriptional

657 Regulation of Antiviral Interferon-Stimulated Genes. *Trends in Microbiology*,

658 25(7), 573–584. <https://doi.org/10.1016/j.tim.2017.01.001>

659 Wernery, U., Kinne, J., & Schuster, R. K. (2014). *Camelid infectious disorders*. OIE

660 (World Organisation for Animal Health).

661 Wu, H., Guang, X., Al-Fageeh, M. B., Cao, J., Pan, S., Zhou, H., Zhang, L.,

662 Abutarboush, M. H., Xing, Y., Xie, Z., Alshanqeeti, A. S., Zhang, Y., Yao, Q., Al-

663 Shomrani, B. M., Zhang, D., Li, J., Manee, M. M., Yang, Z., Yang, L., ... Wang, J.
664 (2014). Camelid genomes reveal evolution and adaptation to desert environments.
665 *Nature Communications*, 5. <https://doi.org/10.1038/ncomms6188>
666 Zhou, Z., Hamming, O. J., Ank, N., Paludan, S. R., Nielsen, A. L., & Hartmann, R.
667 (2007). Type III Interferon (IFN) Induces a Type I IFN-Like Response in a
668 Restricted Subset of Cells through Signaling Pathways Involving both the Jak-
669 STAT Pathway and the Mitogen-Activated Protein Kinases. *Journal of Virology*,
670 81(14), 7749–7758. <https://doi.org/10.1128/jvi.02438-06>
671 Zhu, S., Zimmerman, D., & Deem, S. L. (2019). A Review of Zoonotic Pathogens of
672 Dromedary Camels. *EcoHealth*, 16(2), 356–377. <https://doi.org/10.1007/s10393-019-01413-7>
673
674
675 **Table 1.** Features of the selected cytokines and immune genes used for gene expression
676 analyses, and their validated primer pair sequences for all camelid species.
677
678 **Table S1.** NCBI accession numbers of camelid gene sequences used for comparative
679 analyses and primer design.
680
681 **Table S2.** Features of the primer pairs designed for the quantification of camelid
682 immune and reference genes by RT-qPCR.
683
684 **Table S3.** Performance of the primer pairs designed for the quantification of mRNA
685 expression of camelid immune and reference genes.
686

687 **Table S4.** Expression level of immune response genes from alpaca, dromedary camel
688 and llama PBMCs stimulated with PHA, PMA-/ionomycin or PolyI:C.

689

690 **Figure 1.** Relative expression of llama immune genes by microfluidic RT-qPCR. Gene
691 expression profile of llama (L1-2) PBMCs stimulated for 48 h with PHA or PMA-
692 ionomycin were compared to that from unstimulated cells. The relative standard curve
693 method was applied for normalization purposes using multiple reference gene
694 normalization (*GAPDH*, *HPRT1* and *UbC*). Immune genes were grouped by functional
695 categories: (a) IFNs, (b) PRRs, (c) ISGs, inflammatory (d) chemokines and (e)
696 cytokines, (f) transcription factors, downstream signalling (g) adaptors and (h) enzymes,
697 (i) cellular receptors, and (j) cytokines involved in Th1 and Th2 response. Black and
698 grey bars display differential expression of PHA and PMA-ionomycin stimulated
699 PBMCs, respectively, relative to unstimulated cells. Relative expression data is
700 displayed as mean fold-change differences \pm SD. IFN, interferon; ISG, interferon-
701 stimulated gene; PBMCs, peripheral blood mononuclear cells; PHA,
702 phytohemagglutinin; PMA, phorbol 12-myristate 13-acetate; PRR, pattern-recognition
703 receptor.

704


705 **Figure 2.** Relative expression of alpaca (A1-5) immune genes by microfluidic RT-
706 qPCR. Immune gene expression profile of alpaca PBMCs stimulated with PHA (A1-2,
707 black bars), PMA-ionomycin (A1-2, grey bars), or PolyI:C (A3-5, empty bars) for 48 h
708 were compared to that from non-stimulated cells. The relative standard curve method
709 was applied for normalization purposes using multiple reference gene normalization
710 (*GAPDH*, *HPRT1* and *UbC*). Immune genes were grouped by functional categories: (a)
711 IFNs, (b) PRRs, (c) ISGs, inflammatory (d) chemokines and (e) cytokines, (f)

712 transcription factors, downstream signalling (g) adaptors and (h) enzymes, (i) cellular
713 receptors, and (j) cytokines involved in Th1 and Th2 response. Relative expression data
714 is displayed as mean fold-change differences \pm SD. Statistical significance was
715 determined by unpaired t-test. *indicates p -value < 0.05 ; **indicates p -value < 0.01 ;
716 ***indicates p -value < 0.001 compared with control samples obtained prior cell culture.
717 IFN, interferon; ISG, interferon-stimulated gene; PBMCs, peripheral blood
718 mononuclear cells; PHA, phytohemagglutinin; PMA, phorbol 12-myristate 13-acetate;
719 PRR, pattern-recognition receptor.


720

721 **Figure 3.** Relative expression of dromedary camel (D1) immune genes by microfluidic
722 RT-qPCR. Immune gene expression profile of dromedary PBMCs stimulated with PHA
723 (black bars) or PMA-ionsomycin (grey bars) for 48 h were compared to that from non-
724 stimulated cells. The relative standard curve method was applied for normalization
725 purposes using multiple reference gene normalization (*GAPDH*, *HPRT1* and *UbC*).
726 Immune genes were grouped by functional categories: (a) IFNs, (b) PRRs, (c) ISGs,
727 inflammatory (d) chemokines and (e) cytokines, (f) transcription factors, downstream
728 signalling (g) adaptors and (h) enzymes, (i) cellular receptors, and (j) cytokines involved
729 in Th1 and Th2 response. Relative expression data is displayed as mean fold-change
730 differences \pm SD. Statistical significance was determined by unpaired t-test. *indicates
731 p -value < 0.05 ; **indicates p -value < 0.01 ; ***indicates p -value < 0.001 compared with
732 control samples obtained prior cell culture. IFN, interferon; ISG, interferon-stimulated
733 gene; PBMCs, peripheral blood mononuclear cells; PHA, phytohemagglutinin; PMA,
734 phorbol 12-myristate 13-acetate; PRR, pattern-recognition receptor.


a)




b)




c)




d)




e)




f)




g)




h)




i)




j)




a)




b)




c)




d)




e)




f)




g)




h)




i)




j)




a)




b)




c)




d)




e)




f)




g)



h)



i)



j)




Table 1. Features of the selected cytokines and immune genes used for gene expression analyses, and their validated primer pair sequences working for all camelid species.

Gene ^(a)	Cytokine/Protein type and function	Primer	Sequence (5' - 3')
<i>GAPDH</i>	Normalizer gene	GAPDH F	GGTCGGAGTGAACGGATTGG
		GAPDH R	TTGAGGTCAATGAAGGGGTCG
<i>UbC</i>	Normalizer gene	Ubc F	AGGCAGAAATCCAAGACAAGG
		Ubc R	CCAAGTGCAGAGTGGATTCT
<i>HPRT1</i>	Normalizer gene	HPRT1 F	CAAAGATGGTCAAGGTCGCAA
		HPRT1 R	TCAAATCCAACAAAGTCTGGTCT
<i>IFN-α</i>	Type I IFN, antiviral	IFN- α F	TCTTCAGCGAGACACTTGCAA
		IFN- α R	GTTGGTCAGTGAGAATCATTTCCA
<i>IFN-β</i>	Type I IFN, antiviral	IFN- β F2	GCATCCTCCAAATCGCTCTCC
		IFN- β R2	ATGCCAAGTTGCTGCTCCTT
<i>IFN-γ</i>	Type II IFN, antiviral activity, and mediator of cellular immunity	IFN- γ F	ACTGGAAAGAGGAGAGTGACAAA
		IFN- γ R	CAACCGGAATTGAAATCAGCT
<i>IFN-λ1</i>	Type III IFN, antiviral	IFN- λ 1 F	CTGCCACATGGGCTGGTT
		IFN- λ 1 R	CGATTCTCCAAGGCATCCTT
<i>IFN-λ3</i>	Type III IFN, antiviral	IFN- λ 3 F	CCACCTGGCCCAATTCAA
		IFN- λ 3 R	AGTGAACCTTCAAAGGCCTCCTT
<i>RIG-1</i>	PRRs and ISG, recognises dsRNA and ssRNA; induce IFN production and ISG	RIG-1 F	ACAAGTCAGAACACAGGAATGA
		RIG-1 R	CTCTCCTCTGCTCTGGTTT
<i>MDA5</i>	PRRs and ISG, recognises dsRNA and ssRNA; induce IFN production and ISG	MDA5 F	ACACCAGAGTCAAAGAGACTGTAT
		MDA5 R	CACCATCATCGTCCCCAAGA
<i>MAVS</i>	PRRs, interacts with RIG-1	MAVS F	CAGCCTCCACAACTGCTACAGA
		MAVS R	CTGTGGGACTTCTTGAACCTCT
<i>TLR3</i>	PRRs and ISG, recognises dsRNA; induce IFN production and ISG	TLR3 F	AGAAATAGACAGACAGCCAGAG
		TLR3 R	TGCTCCCTTGATGCTTTAACGA
<i>TLR7</i>	PRRs and ISG, recognises ssRNA induce IFN production and ISG	TLR7 F	AGAGAGGAGTCACCAGCGTAT
		TLR7 R	GACACAAATGCAAATGGAGAC
<i>NLRP3</i>	PRRs, increased expression of pro-inflammatory cytokines	NLRP3 F	ATGGCCACATGGATTTC
		NLRP3 R	AAACATTGGCATTGCCCCATT
<i>STAT1</i>	Transcription factor activated by IFNs; increased expression of ISG	STAT1 F	TCTCTGTGTCGAAGTTCACCT
		STAT1 R	GGGAATCACAGGTGGAAAGGA
<i>IRF3</i>	Transcription factor and ISG, activated by IFNs; increased expression of ISG	IRF3 F	TCACCAAGCTACACCTCTGGT
		IRF3 R	GAGGCACATGGGCACAACCTGA
<i>IRF5</i>	Transcription factor and ISG, activated by IFNs; increased expression of ISG	IRF5 F	TCAGAAGGCCAGACCAACACC
		IRF5 R	TGCTACGGCACACCTGTA
<i>IRF7</i>	Transcription factor and ISG, activated by IFNs; increased expression of ISG	IRF7 F	CGTGATGTTGCAAGACAACTCA
		IRF7 R	TGGTTAACGCCCTGGCTCT
<i>NFKB1</i>	Transcription factor activated by IFNs; increased expression of pro-inflammatory cytokines	NFKB1 F	GGGACAGTGTCTTACACTAGCAATC
		NFKB1 R	CATCAGAAATCAAGCCAGATGTG
<i>RELA</i>	Transcription factor, binds to NF- κ B	RELA F	AGAGTCCTTCAATGGCCCCACCG
		RELA R	GGATGGAAGTTGAGCTGCGGG
<i>IKBKB</i>	Transcription factor activated by IFNs; increased	IKBKB F	TAATGAACGAAGACGAGAAGATGGT

	expression of pro-inflammatory cytokines	IKBKB R	ACCTTGCTACACGCAATCTTCAG
<i>CXCL10</i>	ISG, activation and migration of immune cells to the infected sites	CXCL10 F	CGTGTGAGATTATTGCCACAATG
		CXCL10 R	GAGGTAGCTCTCTGGTCCT
<i>MX1</i>	ISG, GTPase with antiviral activity	MX1 F	GAAGATGGTTATTCTGACTCG
		MX1 R	TTCTCCTCGTACTGGCTGT
<i>OAS1</i>	ISG, antiviral enzyme; degrades viral RNA	OAS1 F	TGAAGAACGACTCGGGAAAC
		OAS1 R	AGTAACGTCTTCTGGGCAGC
<i>ISG15</i>	ISG, antiviral activity	ISG15 F	CACAGCCATGGGTGAAATC
		ISG15 R	CAGCTCCGATAACAGCATGGA
<i>IL-10</i>	Interleukin, inflammatory antagonist	IL-10 F	CTGCTGGAGGACTTTAAGGGT
		IL-10 R	AGGGGAGAAATCGATGACAGC
<i>IL-18</i>	Interleukin, pro-inflammatory response	IL1-beta F	AGGATATGAGCCGAGAAGTGGT
		IL1-beta R	CCCTTCATCAACAAGACAGGT
<i>IL-6</i>	Interleukin, pro-inflammatory response	IL-6 F	TCTGGGTTCAATCAGGAGACCT
		IL-6 R	AGGGGTGCTTACTTCTCTGGT
<i>IL-8</i>	Interleukin, pro-inflammatory response	IL-8 F	TGTGTGAAGCTGCAGTTCTGT
		IL-8 R	GCAGACCTCTTCCATTGGC
<i>IL-15</i>	Interleukin, induces proliferation of antiviral natural killer cells	IL-15 F	CAGCCTACAGAAGGTATGAAGTACTC
		IL-15 R	GGGTAACCTCTTAAGTATCGAAGAAGAG
<i>IL-2</i>	Interleukin, cell-mediated immunity	IL-2 F	AAACTCTCCAGGATGCTCAC
		IL-2 R	TTTCAGATCCCTCAGTTCC
<i>IL-4</i>	Interleukin, humoral immunity mediator	IL-4 F	CCCTGGTCTGTTACTGGTTT
		IL-4 R	TCTCAGTCGTGTTCTTGGGG
<i>IL-12p35</i>	Interleukin, cell-mediated immunity	IL-12p35 F2	AATCACCTGGACCACCTCAGT
		IL-12p35 R2	TCTAGGGTTTGCTGGCCTTC
<i>TNF-α</i>	Cytokine, pro-inflammatory response	TNF- α F	TGGCCCAGACCCCTCAGATCA
		TNF- α R	TTCCAGCTTCACACCATTGGC
<i>CCL2</i>	Chemokine, recruits monocytes and dendritic cells at the sites of inflammation	CCL2 F	CCAGTAAGAACATCCCCATGCA
		CCL2 R	GTGTGGCTTGAAGATCACAGCTT
<i>CCL3</i>	Inflammatory chemokine, attracts monocytes, macrophages and neutrophils	CCL3 F	GCTCAGCGTCATGCAGGTGCC
		CCL3 R	AGCAGGCGGTTGGGGTGTAG
<i>CXCL1</i>	Chemokine, attracts neutrophils	CXCL1 F	CGTGCAGGAATTCACTCAA
		CXCL1 R	GAGAGTGGCTACGACTCCGTTT
<i>MIF</i>	Anti-inflammatory cytokine, macrophage migration inhibitory factor	MIF F	GCGAGTTGGTCGGTTCTGTGTT
		MIF R	ACCACGTGCACTCGATGTACT
<i>CASP1</i>	Enzyme, initiates inflammatory responses	CASP1 F	ACTCCACCAA GACCTAACCAAGT
		CASP1 R	GGGTAAATCTCGCTGACTTCTCG
<i>CASP10</i>	Enzyme, involved in apoptosis and inflammation	CASP10 F	CGGTAGCCACGGGAACTGAGTCAT
		CASP10 R	ATCTTGGCAGGACCCCTCGAT
<i>CYLD</i>	Enzyme, involved in transcription factor NF- κ B activation	CYLD F	TCGGGATGGTGGTCAGAACGGC
		CYLD R	AGTCTTCGTGCACAGCCCTGGAT
<i>AZI2</i>	Enzyme, NF- κ B-activating kinase-associated Protein 1	AZI2 F	TGAGCGTCTCCAGCGCTAA
		AZI2 R	CTGCACCTCGTGTACCCAGAT
<i>PACT</i>	Enzyme, protein kinase activated by double-stranded RNA	PACT F	TGCAGTCCTGACCCCTTAATG
		PACT R	GATGAATAGCCAGTTCTGTAGTGAA

<i>TBK1</i>	Enzyme, activates the transcription factor IRF3	TBK1 F	GTACAGAAAGCAGAAAATGGACCAA
		TBK1 R	AACTGAAAGGCCCGAGAAA
<i>TRIM25</i>	Enzyme and ISG, ubiquitination of RIG-1	TRIM25 F	GCCCCGAGCTCCTACAGTATGC
		TRIM25 R	GAAGCGACGGTAGGTCTTG
<i>NFKBIA</i>	NF-κB inhibitor	NFKBIA F	TCCCTCTTCCCCGCAGGTT
		NFKBIA R	TGGAGTGGAGTCTGCTGCAGGT
<i>TRADD</i>	Adaptor, mediates NF-κB activation and apoptosis	TRADD F	CGGCCAGGAAGCAAGATG
		TRADD R	TGAAGACTCCACAAACAGGTATGC
<i>CARD9</i>	Adaptor, activates pro-inflammatory and anti-inflammatory cytokines through NF-κB	CARD9 F	GGCAGTGCAAGGTCTGAAC
		CARD9 R	CAGGAGCACACCCACTTCC
<i>PYCARD</i>	Adaptor, activates caspases and inflammasome	PYCARD F	CAAGCCAGCACCGCACTT
		PYCARD R	TCTGTCAGGACCTTCCATACA
<i>IFNLR1</i>	Cellular receptor of type III IFNs	IFNLR1 F	CAGGGTGTGATCTGGAAGAG
		IFNLR1 R	GTCTGTCAGAGAAATCCAGG
<i>IFNAR1</i>	Cellular receptor of type I IFNs	IFNAR1 F	TGCGAGGAACCAAACAGGAAAT
		IFNAR1 R	ACGACGACGATACAAAACACCGC

(a) Genes have been grouped in functional categories: Normalizer genes, IFNs, pattern recognition receptors, transcription factors, IFN-stimulated genes, pro- and anti-inflammatory cytokines, enzymes, adaptors and cellular receptors. dsRNA, double-stranded RNA; IFN, interferon; ISG, interferon-stimulated gene; PRR, pattern recognition receptor; ssRNA, single-stranded RNA.